Лонкастуксимаб тесирин

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

DB16222

N (не классифицировано FDA)

1879918-31-6

immunoglobulin G1-kappa, anti-[Homo sapiens CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer SCX;
gamma1 heavy chain (1-449) [Mus musculus VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfide with kappa light chain (1'-211') [Mus musculus V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -Homo sapiens IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211')]; dimer (229-229'':232-232'')-bisdisulfide; conjugated, on an average of 2 to 3 cysteines, to the pyrrolobenzodiazepine (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8)

C₆₅₄₄H₁₀₀₄₈N₁₇₁₈O₂₀₆₄S₅₂

147481,45 г/моль

Поделиться этой страницей